{"id":"i-131-metaiodobenzylguanidine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (thrombocytopenia, neutropenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypothyroidism"},{"rate":null,"effect":"Salivary gland dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MIBG (metaiodobenzylguanidine) is taken up by the norepinephrine transporter on neuroendocrine tumor cells, allowing the radioactive iodine-131 to concentrate in these tumors. The beta radiation emitted by I-131 then delivers cytotoxic doses directly to the malignant cells while minimizing exposure to surrounding healthy tissue. This targeted radiopharmaceutical approach is particularly effective for neuroendocrine tumors including neuroblastoma and pheochromocytoma.","oneSentence":"I-131 MIBG is a radioactive iodine-labeled compound that selectively accumulates in neuroendocrine tumors and delivers targeted radiation therapy to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:18.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory high-risk neuroblastoma"},{"name":"Metastatic pheochromocytoma and paraganglioma"}]},"trialDetails":[{"nctId":"NCT00107289","phase":"PHASE2","title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":200},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15},{"nctId":"NCT07261241","phase":"PHASE2","title":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","status":"NOT_YET_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2026-07-31","conditions":"Neuroblastoma","enrollment":118},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":30},{"nctId":"NCT03165292","phase":"PHASE2","title":"Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-10-01","conditions":"Very High Risk Neuroblastoma","enrollment":34},{"nctId":"NCT01163383","phase":"","title":"131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol","status":"AVAILABLE","sponsor":"John Maris","startDate":"","conditions":"Neuroblastoma, Childhood Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT01370330","phase":"","title":"131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol","status":"AVAILABLE","sponsor":"Kieuhoa Vo","startDate":"","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT02378428","phase":"PHASE2","title":"MIBG Therapy for Patients With MIBG Avid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2014-03-01","conditions":"MIBG Avid Tumors","enrollment":65},{"nctId":"NCT03332667","phase":"PHASE1","title":"MIBG With Dinutuximab +/- Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2018-09-12","conditions":"Neuroblastoma","enrollment":45},{"nctId":"NCT06000787","phase":"NA","title":"MCT for the Harvard/UCSF ROBIN Center","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-09-19","conditions":"Glioma, Childhood Brainstem, Neuroblastoma","enrollment":47},{"nctId":"NCT03649438","phase":"","title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","status":"NO_LONGER_AVAILABLE","sponsor":"University of Texas Southwestern Medical Center","startDate":"","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT06669481","phase":"","title":"Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-01","conditions":"Pheochromocytoma, Paraganglioma","enrollment":159},{"nctId":"NCT03015844","phase":"","title":"A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma","status":"AVAILABLE","sponsor":"Northwell Health","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":""},{"nctId":"NCT04614766","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"David Bushnell","startDate":"2022-09-30","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT00509353","phase":"PHASE1","title":"N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2007-01","conditions":"Neuroblastoma","enrollment":26},{"nctId":"NCT01838187","phase":"","title":"Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","status":"NO_LONGER_AVAILABLE","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT03044977","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bushnell","startDate":"2017-05-07","conditions":"Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting","enrollment":20},{"nctId":"NCT00253435","phase":"PHASE2","title":"N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2005-09","conditions":"Neuroblastoma","enrollment":50},{"nctId":"NCT01019850","phase":"PHASE1","title":"N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2010-03","conditions":"Neuroblastoma","enrollment":27},{"nctId":"NCT01590680","phase":"","title":"Expanded Access Protocol Using 131I-MIBG","status":"AVAILABLE","sponsor":"Jubilant DraxImage Inc.","startDate":"","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT03561259","phase":"PHASE2","title":"A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects","status":"UNKNOWN","sponsor":"Jubilant DraxImage Inc.","startDate":"2019-10-21","conditions":"Neuroblastoma, Neuroectodermal Tumors, Neoplasms","enrollment":60},{"nctId":"NCT02035137","phase":"PHASE2","title":"131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2014-07","conditions":"Neuroblastoma","enrollment":114},{"nctId":"NCT04831567","phase":"PHASE2","title":"Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"AC Camargo Cancer Center","startDate":"2021-02-04","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT03923257","phase":"PHASE1, PHASE2","title":"Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2020-08-04","conditions":"Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT01583842","phase":"EARLY_PHASE1","title":"124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study","status":"TERMINATED","sponsor":"Miguel Pampaloni","startDate":"2013-04-09","conditions":"Neuroblastoma","enrollment":10},{"nctId":"NCT00790413","phase":"EARLY_PHASE1","title":"Haploidentical Stem Cell Transplantation in Neuroblastoma","status":"UNKNOWN","sponsor":"Lund University Hospital","startDate":"2005-08","conditions":"Neuroblastoma","enrollment":15},{"nctId":"NCT01377532","phase":"","title":"Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma","status":"APPROVED_FOR_MARKETING","sponsor":"University of California, San Francisco","startDate":"","conditions":"Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT00874614","phase":"PHASE2","title":"A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma","status":"UNKNOWN","sponsor":"Molecular Insight Pharmaceuticals, Inc.","startDate":"2009-06-04","conditions":"Pheochromocytoma, Paraganglioma","enrollment":74},{"nctId":"NCT01313936","phase":"PHASE1","title":"High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03","conditions":"Neuroblastoma","enrollment":32},{"nctId":"NCT02961491","phase":"","title":"Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma","status":"APPROVED_FOR_MARKETING","sponsor":"Molecular Insight Pharmaceuticals, Inc.","startDate":"","conditions":"Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT00037869","phase":"PHASE3","title":"High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-11","conditions":"Neuroendocrine Tumors, Metastases, Neoplasm","enrollment":15},{"nctId":"NCT01413503","phase":"PHASE2","title":"A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"1991-05","conditions":"Pheochromocytoma, Paraganglioma","enrollment":50},{"nctId":"NCT03061656","phase":"PHASE2","title":"Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-01-01","conditions":"High Risk Neuroblastoma","enrollment":40},{"nctId":"NCT00659984","phase":"PHASE2","title":"N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Molecular Insight Pharmaceuticals, Inc.","startDate":"2008-06","conditions":"Neuroblastoma","enrollment":15},{"nctId":"NCT00028106","phase":"PHASE2","title":"131MIBG to Treat Malignant Pheochromocytoma","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2001-12-05","conditions":"Pheochromocytoma","enrollment":32},{"nctId":"NCT00960739","phase":"PHASE2","title":"Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2008-11","conditions":"Neuroblastoma","enrollment":30},{"nctId":"NCT01099228","phase":"NA","title":"Combination Targeted Radiotherapy in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"David Bushnell","startDate":"2006-09","conditions":"Neuroendocrine Tumors","enrollment":2},{"nctId":"NCT00458952","phase":"PHASE1, PHASE2","title":"Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma","status":"COMPLETED","sponsor":"Molecular Insight Pharmaceuticals, Inc.","startDate":"2007-04","conditions":"Pheochromocytoma, Paraganglioma","enrollment":24},{"nctId":"NCT01941849","phase":"PHASE1","title":"Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2014-10","conditions":"Phaeochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT00992173","phase":"PHASE2","title":"Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma","status":"WITHDRAWN","sponsor":"Molecular Insight Pharmaceuticals, Inc.","startDate":"2010-01","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00526318","phase":"NA","title":"Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2007-01","conditions":"Neuroblastoma","enrollment":360},{"nctId":"NCT00293319","phase":"PHASE2","title":"131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-04","conditions":"Neuroblastoma","enrollment":164},{"nctId":"NCT00410631","phase":"PHASE3","title":"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2004-10","conditions":"Neuroblastoma","enrollment":642},{"nctId":"NCT00389766","phase":"PHASE2","title":"High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma","status":"WITHDRAWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2008-07","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT01448083","phase":"","title":"Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours","status":"UNKNOWN","sponsor":"Nuclear Medicine Consultants, Inc.","startDate":"2011-10","conditions":"Neuroendocrine Tumor","enrollment":40},{"nctId":"NCT00798148","phase":"PHASE1, PHASE2","title":"131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2008-09","conditions":"Neuroblastoma","enrollment":10},{"nctId":"NCT00339131","phase":"PHASE1","title":"ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid","status":"COMPLETED","sponsor":"Molecular Insight Pharmaceuticals, Inc.","startDate":"2006-06","conditions":"Pheochromocytoma, Paraganglioma, Carcinoid","enrollment":24},{"nctId":"NCT00083135","phase":"PHASE1","title":"N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2004-03","conditions":"Neuroblastoma","enrollment":18},{"nctId":"NCT00005978","phase":"PHASE1","title":"N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2000-05","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00013806","phase":"PHASE2","title":"CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"","conditions":"Neuroblastoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":54,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MIBG"],"phase":"phase_3","status":"active","brandName":"I-131 Metaiodobenzylguanidine","genericName":"I-131 Metaiodobenzylguanidine","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"I-131 MIBG is a radioactive iodine-labeled compound that selectively accumulates in neuroendocrine tumors and delivers targeted radiation therapy to kill cancer cells. Used for Relapsed or refractory high-risk neuroblastoma, Metastatic pheochromocytoma and paraganglioma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}